These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 18854267)
1. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267 [TBL] [Abstract][Full Text] [Related]
2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963 [TBL] [Abstract][Full Text] [Related]
3. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431 [TBL] [Abstract][Full Text] [Related]
4. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668 [TBL] [Abstract][Full Text] [Related]
5. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954 [TBL] [Abstract][Full Text] [Related]
6. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734 [TBL] [Abstract][Full Text] [Related]
7. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus]. Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407 [TBL] [Abstract][Full Text] [Related]
8. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology and molecular biology of Barrett esophagus. Casson AG; Williams L; Guernsey DL Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034 [TBL] [Abstract][Full Text] [Related]
10. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma. Abraham SC; Wang H; Wang KK; Wu TT Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141 [TBL] [Abstract][Full Text] [Related]
11. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Dorer R; Odze RD Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330 [TBL] [Abstract][Full Text] [Related]
12. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933 [TBL] [Abstract][Full Text] [Related]
13. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707 [TBL] [Abstract][Full Text] [Related]
14. [Barrett's oesophagus: endoscopic diagnosis and follow-up]. Ponsot P Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849 [TBL] [Abstract][Full Text] [Related]
15. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus. Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478 [TBL] [Abstract][Full Text] [Related]
16. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Lim CH; Treanor D; Dixon MF; Axon AT Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911 [TBL] [Abstract][Full Text] [Related]
17. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. Parenti A; Leo G; Porzionato A; Zaninotto G; Rosato A; Ninfo V Hum Pathol; 2006 Jan; 37(1):16-22. PubMed ID: 16360411 [TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854 [TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cestari R; Villanacci V; Rossi E; Della Casa D; Missale G; Conio M; Grigolato P; Bassotti G Cancer Lett; 2007 Jun; 251(2):278-87. PubMed ID: 17321043 [TBL] [Abstract][Full Text] [Related]
20. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Kerkhof M; van Dekken H; Steyerberg EW; Meijer GA; Mulder AH; de Bruïne A; Driessen A; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD; Histopathology; 2007 Jun; 50(7):920-7. PubMed ID: 17543082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]